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Ex vivo studies of human disease, such as acute myeloid leukemia, are generally limited to 
the analysis of two-dimensional cultures which often misinterpret the effectiveness of 
chemotherapeutics and other treatments. Here we show that matrix metalloproteinase-
sensitive hydrogels prepared from poly(ethylene glycol) and heparin functionalized with 
adhesion ligands and pro-angiogenic factors can be instrumental to produce robust three-
dimensional culture models, allowing for the analysis of acute myeloid leukemia 
development and response to treatment. We evaluated the growth of four leukemia cell lines, 
KG1a, MOLM13, MV4-11 and OCI-AML3, as well as samples from acute myeloid leukemia 
patients. Furthermore, endothelial cells and mesenchymal stromal cells were co-seeded to 
mimic the vascular niche for acute myeloid leukemia cells. Higher drug resistance to 
Daunorubicin and Cytarabine was demonstrated in three-dimensional cultures and in vascular 
co-cultures when compared with two-dimensional suspension cultures, opening the way for 
drug combination studies. Application of the C-X-C chemokine receptor type 4 (CXCR4) 
inhibitor, AMD3100, induced mobilization of the acute myeloid leukemia cells from the 
vascular networks. These findings indicate that the 3D tri-culture model provides a 
specialized platform for the investigation of cell-cell interactions, addressing a key challenge 
of current testing models. This ex vivo system allows for the personalized analysis of patient 
cell responses that provide new insights into acute myeloid leukemia development and 
therapies.  
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Information about clinical trials 
These studies were approved by the institutional review boards of all participating centers of 
the Study Alliance Leukemia in agreement with the Declaration of Helsinki and registered 
with the National Clinical Trial numbers 00180115 (AML96 trial), 00180102 (AML2003 
trial) and 00180167 (AML60+ trial). Written informed consent was obtained from each 
patient. Mesenchymal stromal cells were derived from healthy volunteer donors after 
informed consent. The use of surplus bone marrow cells for MSC generation was approved 
be the ethics committee of the Technical University Dresden, Fetscherstraße 74, 



















At the interface of in vitro culture models and complex animal models are sophisticated ex 
vivo models, which rely on our ability to replicate tissue microenvironments in order to 
sustain the growth of donor cells. Cell-cell and cell-matrix interactions, together with the 
signaling mechanisms between cells residing within spatially distinct niches, are important 
for the analysis of disease development, progression, and drug responses. Acute myeloid 
leukemia (AML) is a disease associated with five-year survival rates of less than 40% in 
adults,1-3 although this figure decreases for adults aged over 65 years to less than 10%.2, 3 
AML is characterized by an uncontrolled expansion of immature blasts resulting in a reduced 
normal blood cell production. Leukemic cell proliferation and resistance to chemotherapy has 
remained difficult to investigate ex vivo4, 5 since conventional 2D cell cultures cannot provide 
long-term maintenance of primary leukemic cells without the support of additional growth 
factors or stromal cells and lack the microenvironmental stimuli of the bone marrow.  
 
Therefore, different bioengineered 3D culture systems have been developed to more 
realistically study AML cells in vitro using, however, stiff and porous materials as scaffolds 
and mono-cultures or co-cultures of AML with mesenchymal stromal cells (MSC).6-8 While 
these previous studies replicated important aspects of the stromal microenvironment, they did 
not allow for the exploration of leukemic-vascular cell-cell interactions which are critical for 
leukemia biology and progression.9 The vascular niche, so-called due to its density of blood 
vessels, is a location where endothelial cells and mural cells, such as pericytes, generate a 
microenvironment that influences the behavior of hematopoietic and leukemic stem and 
progenitor cells.10 In particular, angiogenesis is promoted by the bone marrow stroma and 
leukemic blasts and further increases in conditions such as AML and acute lymphoblastic 
leukemia.11-13 The activation by angiogenic growth factors and cytokines, such as VEGF, 
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SDF-1 and FGF-2, modify the vascular niche to promote malignant growth.14 While a 
relationship between AML and vascular endothelium seems likely to contribute to AML 
progression, understanding of the mechanisms involved in these interactions are still 
lacking.15-17 
 
To recapitulate AML-vascular niche interactions in vitro, we used a set of thoroughly defined 
and widely tunable star-shaped poly(ethylene glycol) (starPEG)-heparin hydrogels18, 19 to 
grow cells from four leukemia lines, KG1a, MOLM13, MV4-11 and OCI-AML3, as well as 
primary cells from AML patients, with human vascular endothelial cells as well as MSC. To 
support the specific requirements of the chosen cell types, the gel matrices were 
functionalized with precisely adjusted amounts of covalently attached adhesion receptor 
ligand peptide (RGD) motifs. MMP-responsive peptide sequences were incorporated as 
hydrogel crosslinkers to allow for localized cellular remodeling, thus supporting proliferation 
and migration of cells within the 3D gel cultures. A combination of growth factors (VEGF, 
FGF-2, SDF-1) known to tightly associate with the glycosaminoglycan heparin was applied 
to customize the gel matrices according to previously established protocols to afford 
sustainable administration resulting in the formation and maintenance of 3D endothelial cell 
capillary networks within the gels.20 To validate the culture model, we determined the impact 
of chemotherapeutics and signaling inhibitors on the tri-culture system and assessed the 
relevance of our findings. We have applied a multi-disciplinary in vitro approach that 
integrates biological and physical techniques with human samples, ultimately extending our 
understanding of the impact of treatments on cell-cell interactions.  
 
Methods 
Culture of cell lines 
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KG1a, MOLM13, MV4-11 and OCI-AML3 cell lines were obtained from the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braunschweig, Germany) and 
used within 15 passages. KG1a, MOLM13 and MV4-11 cells were cultured in medium 
consisting of Roswell Park Memorial Institute (RPMI, Life Technologies, Darmstadt, 
Germany) medium supplemented with GlutaMax (Life Technologies), 10 % fetal bovine 
serum (FBS; Hyclone Thermo Scientific, Schwerte, Germany) and 1 % 
penicillin/streptomycin solution (PS; Life Technologies). OCI-AML3 cells were cultivated in 
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies) supplemented with 10 % 
FBS and 1 % PS.  
 
Culture of primary donor cells 
The studies were approved by the institutional review boards of all participating centers of 
the Study Alliance Leukemia in agreement with the Declaration of Helsinki and registered 
with the National Clinical Trial numbers 00180115 (AML96 trial), 00180102 (AML2003 
trial) and 00180167 (AML60+ trial). Written informed consent had been obtained from each 
patient. Three peripheral blood samples derived from patients with AML were obtained with 
ethical permission from the Uniklinikum Dresden, prepared as previously described,21 frozen, 
and thawed directly for experiments in hydrogels. Primary AML cells were cultured in 
medium consisting of StemSpan SFEM (Stem Cell Technologies, Grenoble, France) 
supplemented with 2% FBS for Human Myeloid Long-Term Culture (Stem Cell 
Technologies), 1% L-Glutamine, 1 % PS solution (both Life Technologies), 10 ng/mL 
FLT3L, 10 ng/mL stem cell factor (SCF), 10 ng/mL thrombopoietin (TPO), and 10 µg/mL 
interleukin 3 (IL3; all R&D Systems, Minneapolis, USA). OCI-AML3 cells were cultivated 
in DMEM supplemented with 10 % FBS and 1 % PS. Human umbilical vein endothelial cells 
(HUVECs) were isolated as previously described22 and cultured in Endothelial Cell Growth 
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Medium (ECGM; Promocell, Heidelberg, Germany). Mesenchymal stromal cells were 
derived from healthy volunteer donors after informed consent. The use of surplus bone 
marrow cells for MSC generation was approved by the ethics committee of the Technical 
University Dresden (Ethics approval ID: EK127042009). Bone marrow-derived MSC were 
isolated as previously described23 and cultured in DMEM supplemented with 10 % FBS and 
1 % PS. HUVECs and MSCs were utilized for experiments between passages 1 - 6. 
 
Chemotherapeutic and signaling inhibitor experiments 
AML 2D mono-cultures, 3D mono-cultures and 3D tri-cultures were tested for 
chemotherapeutic response to AraC and DNR. A dose response curve was first calculated. 
Cytosine β-D-arabinofuranoside (AraC, Cytarabine, dissolved in double distilled water, 
ddH20; Sigma Aldrich) was added to cultures at 0, 5, 20, 100, 500, 1000 and 2000 µM for 24 
hours before a media change. Daunorubicin hydrochloride (DNR, dissolved in ddH20; Sigma 
Aldrich) was added to cultures at 0, 0.01, 0.1, 0.2, 1, 2.5, 5 µM for 24 hours before a media 
change. For both drugs, cell viability was determined at day 5 post-treatment using a 
PrestoBlue assay (described in detail in Supplementary Materials and Methods). For 
signaling inhibitor experiments, AMD3100 (dissolved in ddH20; Sigma Aldrich) was applied 
to cultures at 0 or 2.5 µg per mL in ECGM. Sorafenib (dissolved in dimethyl sulfoxide; Santa 
Cruz, Heidelberg, Germany) was added to cultures at 0 or 1 µM. Cultures were treated with 
AMD3100 or Sorafenib for 7 days, medium was exchanged every second day for fresh 
medium with fresh drug solution. 
 
Statistics 
All statistical analysis was performed using GraphPad Prism v6. Data was analysed using 
either a one-way or two-way analysis of variance (ANOVA) (depending on relevant 
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experiment) with post-hoc Tukey’s multiple comparisons tests. Significance is reported as * 
(p<0.05), ** (p<0.01), *** (p<0.001) or **** (p<0.0001). 
 
Results 
AML-vascular interactions within starPEG-heparin hydrogels. A tri-culture model of 
AML-vascular interactions was established utilizing hydrogels of approximately 200-300 Pa 
stiffness (storage modulus) (Figure 1A), as this stiffness was reported optimal for the 
development of a robust endothelial network20, and preliminary data showed that the 
endothelial cells would not form vascular networks in γ1.0 (1500 Pa) hydrogels (data not 
shown). Hydrogels were stable after casting and easily transferred into medium (Figure 1B). 
All AML cell lines, KG1a, MOLM13, MV4-11 and OCI-AML3 grew similarly within the 3D 
model. The colonization and proliferation of AML cells was visualized via light microscopy 
(Figure 1C) and confocal microscopy (Figure 1D-H) after one week of tri-culture. AML cell 
lines predominantly grew along the HUVEC-MSC vascular network. The AML cell lines 
were determined to proliferate in AML-HUVEC and AML-MSC co-cultures in a similar way 
to the AML-HUVEC-MSC tri-cultures (Figure 2). AML cell proliferation resulted in a 
heterogeneous mixture of spheroids and loose cell clumps in contact with the vascular 
network (Figure 1E-F). Primary donor cells from leukemia patients (pAML) grew more 
slowly than the AML cell lines, resulting in less dense areas of AML-vascular interactions 
(Figure 1I-K). However, pAML cells appeared as clumps within the vascular network 
branching (Figure 1I), rarely formed spheroids, and showed preference for single cell 
adherence and growth to the HUVEC-MSC network (Figure 1J-K). The HUVEC-MSC 




AML cells form spheroids within starPEG-heparin hydrogels. AML mono-culture 
models were generated by culturing KG1a, MOLM13, MV4-11 and OCI-AML3 cells within 
starPEG-heparin hydrogels of various stiffness or in MatrigelTM over two weeks. To 
determine the optimal stiffness for the culture of AML cells within starPEG-heparin 
hydrogels, three different cross-linking degrees were investigated (γ0.75, γ1, and γ1.5, where 
γ is the molar ratio of PEG to heparin). As previously described, the approximate stiffness of 
these cross-linking degrees equate to 500 Pa, 1500 Pa, and 3000 Pa (storage modulus) 
respectively.24 Hydrogels prepared at γ0.75 often disintegrated during the culture period. 
Proliferation was measured using PrestoBlue reagent. Hydrogels prepared at γ1 allowed the 
highest proliferation when compared with 2D cultures and contained spheroids of the largest 
size amongst all crosslinking degrees (Figure 3A-D). MatrigelTM cultures allowed 
consistently the highest proliferation when compared with both 2D cultures and starPEG-
heparin cultures. Human pAML cells derived from three different donors were only cultured 
in γ1 hydrogels. In all three donor samples, a heterogeneous population of cells was present, 
as evidenced by the mixture of spheroids, loose cell clumps, and single cells (Figure 3E). In 
some cases, elongated cells were also present. 
 
AML cells display similar functionality and phenotype between 2D and 3D cultures. 
Migration assays and colony forming assays were performed to determine whether the 
different matrices affected AML migratory abilities and clonogenicity respectively. 
Migration of AML cells cultured in starPEG-heparin hydrogels was decreased when 
compared to 2D cultures (Supplementary Figure S2A; KG1a: 67.51% ± 32.66; MOLM13: 
66.93% ± 38.17; MV4-11: 29.82% ± 15.95; OCI-AML3: 38.27% ± 23.97). This might be due 
to residual hydrogel fragments blocking the pores. In the colony forming experiment, while 
the number of MV4-11 colonies derived from 3D cultures was decreased when compared 
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with 2D cultures (55.45% ± 17.65), KG1a, MOLM13 and OCI-AML3 colony formation was 
not or marginally reduced in 3D cultures (Supplementary Figure S2B-C; 87.08% ± 2.103; 
98.06% ± 0.02; 88.16% ± 42.73). Flow cytometry analysis of 3D and 2D mono-cultures 
showed a similar marker expression with the following exceptions. MOLM13 3D mono-
cultures displayed higher mean fluorescence intensities (MFI) of CD33 and CD54, while 
MOLM13 2D cultures displayed higher MFI of CD29 (Supplementary Figure S3A). MV4-11 
2D cultures showed higher MFI of HLA-DR and CD29 when compared with 3D cultures. 
OCI-AML3 2D cultures demonstrated higher MFI of CD45 and CD54 than 3D cultures. 
Positive expression of target antigens in AML 3D and 2D cultures is detailed in 
Supplementary Table S1. Immunostaining for Integrin α4, CD44 and CD54 was similar 
between all AML cells (Supplementary Figure S3B). Higher MFI of CD45 and HLA-DR was 
found in mono-cultures and higher MFI of CD49e and CD29 was found in pAML tri-cultures 
compared to mono-cultures. Immunostaining revealed similar expression of CD44 and CD34 
in all three donors (Supplementary Figure S3C). 
 
AML 3D tri-cultures demonstrate increased resistance to Daunorubicin (DNR) and 
cytosine β-D-arabinofuranoside (AraC, Cytarabine). The AML γ0.63 tri-cultures and γ1 
mono-cultures were treated with a 7 different doses of DNR or AraC in comparison with 2D 
mono-cultures for 24 hours. AML cells cultured in 2D were most sensitive to the drug doses 
applied when compared with the 3D mono-cultures and tri-cultures (Figure 4B). Significant 
differences were found between KG1a 2D and 3D tri-culture cell viability after treatment 
with 0.20 µM DNR (Figure 4B), and at all AraC concentrations tested except for 1,000 µM 
(Supplementary Figure S4B). MOLM13 tri-cultures were significantly more resistant than 2D 
cultures when treated with 0.10, 0.20 or 1.00 µM of DNR (Figure 4B), and at most AraC 
concentrations (Supplementary Figure S4B). MV4-11 3D tri-cultures had a significantly 
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higher number of viable cells than 2D mono-cultures when treated with 0.01, 0.10, 0.20, 
1.00, or 5.00 µM DNR (Figure 4B), and at all AraC doses tested (Supplementary Figure 
S4B). OCI-AML3 3D tri-cultures displayed higher numbers of viable cells at 0.10 and 0.20 
µM DNR treatment (Figure 4B), and significantly increased resistance at all AraC 
concentrations tested when compared with 2D mono-cultures (Supplementary Figure S4B). 
AML spheroid size in mono-cultures was inversely correlated with DNR concentration 
(Figure 4A, C). Generally, EC50 values for tri-cultures were increased in all cell lines when 
compared with 2D and 3D mono-cultures (Table 1). While pAML donors 1 and 2 only 
demonstrated reduced cell viability at 5.00 µM DNR, pAML donor 3 had an increased 
susceptibility to DNR treatment with reduced cell viability at both 0.20 and 5.00 µM (Figure 
4D). Donor 1 demonstrated resistance to AraC therapy, while donor 2 showed a trend 
towards decreased cell viability upon treatment (Supplementary Figure S4D). The binding 
constants (Kb) for DNR and AraC to the hydrogels reflect the hydrophilic character and 
number of positively charged groups of the molecules (Table 2). AraC has a higher Kb than 
DNR, thus indicating that AraC has a slightly higher affinity to the hydrogels (stronger 
electrostatic interaction with heparin) than DNR. The lower the affinity of a drug to the 
hydrogels, the easier it is for the drug to diffuse through the hydrogels (Supplementary Figure 
S7). 
 
CXCR4 antagonist, AMD3100, induced AML mobilization from the vascular network 
but failed to increase DNR efficiency in 3D tri-cultures. The CXCR4/CXCR12 axis is 
thought to be the mechanism through which leukemia cells are protected from 
chemotherapeutics by the stromal microenvironment.25-27 Therefore, antagonists targeting 
this mechanism (eg. AMD3100) have been developed for use in combination with 
chemotherapy such as AraC or DNR.28, 29 Sorafenib a multi-tyrosine kinase inhibitor, has also 
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been shown to provide antileukemic efficacy when added to standard chemotherapy.30 The 
application of AMD3100 significantly reduced AML-vascular contact in KG1a, MOLM13 
and MV4-11 cultures (Figure 5A-B). When OCI-AML3 cultures were treated with 2.5 µg/mL 
AMD3100, a contrasting effect occurred whereby AML-vascular contact significantly 
increased upon treatment (Figure 5B). Similar results were found for the pAML cultures 
(Figure 5C). Donors 1 and 3 both displayed decreased AML-vascular contact upon 
application of AMD3100, while donor 2 showed increased contact (Figure 5C-D). Numbers 
of viable cells remained unchanged in all three donors after AMD3100 treatment (Figure 
5D). Using 3D analysis, no changes in vascular network volume were visualized 
(Supplementary Figure S8). However using 2D maximum projection analysis, increased 
percentage vessel area was found in KG1a and OCI-AML3 and increased total vessel length 
was found in OCI-AML3 after AMD3100 treatment (Supplementary Figure S8). In the 
pAML cultures, 3D analysis showed increased network volume in Donors 1 and 2 and 
decreased network volume in Donor 3 (Supplementary Figure S9). Using 2D analysis, Donor 
1 and 3, but not Donor 2, showed decreased vessel area and length upon treatment with 
AMD3100 (Supplementary Figure S9). CXCR4 expression was similar between MOLM-13, 
MV4-11 and OCI-AML3 cell lines, whereas some heterogeneity was seen between pAML 
donors 1 and 2 (Supplementary Figure S10). When AMD3100 or Sorafenib was utilized as a 
pre-treatment for DNR, no significant increase in DNR toxicity was quantified for all cell 
lines tested (Supplementary Figure S5A-B). The binding constants for AMD3100 and 
Sorafenib to the starPEG-heparin hydrogels are described in Table 2. AMD3100 has a higher 
Kb than Sorafenib, thus indicating that AMD3100 has a higher affinity to the hydrogels 




Combination of DNR and AraC treatment resulted in complete ablation of AML 3D tri-
cultures. To mimic the clinical scenario as closely as possible, the approximate values for 
standard induction therapy, combination of AraC and DNR, were calculated for traditional 
human and murine treatments and applied to the 3D cultures based upon the dimensions of 
the hydrogels (Figure 6A). Five days post-treatment, the percentage of live cells was 
approximately 10% and below (Figure 6B). Tri-cultures were maintained in normal medium 
for 14 days post-treatment to examine any relapse or regrowth of AML cells. However, at 
day 14 post-treatment, cell activity was completely obliterated, or in any case under the 
detection limit for the cell viability assay. Similar results were observed in the pAML 
cultures, with all three donors showing little to no metabolically active cells five days post-
treatment (Figure 6C). 
 
Discussion 
Vascular endothelial cells are a critical component of the hematopoietic microenvironment 
that regulate blood cell production. The stromal microenvironment promotes malignant 
progression through signaling factors, cell-matrix and cell-cell interactions or alterations in 
the surrounding matrix.31 Although the role of the stromal microenvironment in solid tumor 
development and progression is well established,32-34 the role of the stromal niche in AML 
progression is relatively unknown. Cell-cell interactions between the vascular niche and 
malignant cell types may play an important role in the pathophysiology of AML. Higher 
microvascular density is known to occur in the bone marrow microenvironment of patients 
with hematological malignancies,12, 35 and may correlate with resistance to therapy.36 
Signaling cross-talk between endothelial and AML cells has been demonstrated in in vitro 
cultures.37-39 Therefore, AML-vascular niche interactions in AML progression define a 
pressing area of research.9  
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The growth and capillary network formation of HUVECs within the applied platform of 
biohybrid glycosaminoglycan hydrogels has previously been demonstrated.20 Typically, 
HSCs are found in the vicinity of vascular endothelium.40 In fact, endothelial cells are 
reported to increase the proliferation of AML cells when in co-culture.41 AML cells have a 
reduced cell cycle activity once attached to the endothelial cells and are protected from 
standard chemotherapy. In this context, our results demonstrate the preference for AML cells 
to adhere to and proliferate on the endothelial network. While pAML cells did not proliferate 
as fast as the cell lines, they remained in close proximity to the endothelial network. Future 
studies may explore the role of specific integrins and adhesion molecules in the attachment of 
AML cell to the vascular endothelium and their localization during 3D mono- and tri-
cultures, and integrin inhibition may reveal specific cascades promoting AML-vascular 
interactions. 
 
In this study, four different AML cell lines were tested to represent various subtypes of 
AML.42 KG1a, an M0 classified immature AML cell line, MOLM13, an M5a classified AML 
cell line known as acute monocytic leukemia, MV4-11, an M5 classified cell line derived 
from biphenotypic B-myelomonocytic leukemia, and OCI-AML3, an M4 classified AML 
known as acute myelomonocytic leukemia. In this study, pAML cells derived from three 
different patients were utilized for the various experiments (Supplementary Table S2). Donor 
1, was a 77 year old male with M2 classified AML (with myelodysplasia-related changes) 
harvested from the bone marrow at initial diagnosis. The AML was FLT3-ITD negative. 
Donor 2, was a 65 year old male with M1 classified AML (without maturation) harvested 
from the peripheral blood at initial diagnosis. The AML was FLT3-ITD negative. Donor 3, 
was a 75 year old male with M1 classified AML (with myelodysplasia-related changes) 
15 
harvested from peripheral blood at a progressive/refractory stage of disease. Molecular 
genetics analysis was not available for this donor due to a lack of molecular testing. When 
comparing the growth of the four AML cell lines tested, the cell viability was reduced in 3D 
cultures when compared with 2D cultures. AML cells grown within MatrigelTM developed 
loose clumps of cells, whereas in hydrogels the cells formed tight spheroids. When pAML 
cells were cultured within our customized biohybrid hydrogels, a heterogeneous population 
developed, which is typical of an un-sorted peripheral blood sample. These results underline 
the softer mechanical properties and inherent growth factor presence within MatrigelTM in 
comparison with our glycosaminoglycan-based hydrogels. The established hydrogel mono-
cultures, when cultured to specific time points, effectively allow for producing AML 
spheroids at different sizes for subsequent studies.  
 
Within our culture model, the AML tri-culture displayed increased resistance at some DNR 
concentrations using MOLM-13 and MV4-11 cell lines when compared with 2D and 3D 
mono-cultures, and to a lesser extent in OCI-AML3 cell lines. However, this effect was not 
visualized in KG1a cultures. Moreover, when AraC was applied, our 3D model did not show 
decreased cell viability, although an increase in treatment concentration or duration of 
treatment may expose different effects. These findings are similar to that reported by 
previous research groups, who suggest that AML cells that are adherent to endothelial cells 
become more resistant to AraC.17, 43 Moreover, cell adhesion-mediated drug resistance to the 
HUVECs and MSCs, regulated by integrins, can lead to a decrease in chemotherapeutic 
response.44 Another important method for clinical AML treatment, is the use of CXCR4 
antagonists to block the CXCR4/CXCL12 axis and prevent AML cells from niche protection, 
and thus in theory making combination therapies more effective. In our hydrogel based 3D 
tri-culture model, a significant increase in AML mobilization was observed when AMD3100 
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was applied to the cultures, except in the case of OCI-AML3. In this case, it could be that 
AMD3100 affects this subtype of AML in an opposing manner, and this method of treatment 
would not be recommended clinically. Although, due to the high expression of CXCR4 on 
the surface of OCI-AML3 cells, also associated with poor prognosis,45, 46 it could be that a 
more potent antagonist is required.47 It is important to note that differences in HUVEC/MSC 
network density were sometimes visualized between leukemia cell types in these 
experiments. Therefore, it may be possible that AMD3100 is in fact altering the network 
structures, thus making it more difficult for leukemia cells to come into contact with the 
network, rather than inducing mobilization of leukemia cells. More in-depth 3D 
quantification is required to analyze microenvironmental changes in the future and further 
studies are required to determine the mechanistic effects of AMD3100 on different AML 
subtypes. 
 
Other than the application of AMD3100, there are several clinically relevant aspects to our 
study. Induction treatment is performed on AML patients as a ‘first line’ therapy. Usually, 
induction therapy results in ablation of the bulk of malignant cells in order to remove the 
leukemia from the patients’ hematopoietic system. To eradicate the residual leukemic cells, 
further consolidation therapy is applied to ideally extinguish even minimal residual disease 
(MRD) and achieve cure. Our data here show the effectiveness of equivalent induction 
therapy doses on our 3D microenvironment model, and complete ablation of leukemia cell 
lines without re-growth after 2 weeks. Future experiments should explore the development of 
long-term cultures (3-6 months) and the effects of induction therapy, relapse and 
consolidation therapy. As the MRD status after chemotherapy is of major prognostic 
significance,48 the biology and dynamics of residual leukemia cells after therapy could be an 
interesting application of the novel tri-culture model. 
17 
 
Using specimens from AML patients as well as cell lines, we provide experimental evidence 
supporting the clinical relevance of our results. We have demonstrated not only that AML 
interactions with vascular endothelial cells are modulated by the CXCR4/CXCL12 axis 
within our engineered microenvironments, but also that not all subtypes of AML respond in 
the same way. We must also state the limitations of the study here, where pAML studies were 
performed with three patient samples in parallel triplicates, therefore the conclusions drawn 
from our studies should be considered exploratory. Although detailed risk classifications 
mainly based on genetic abnormalities have been shown to project accurately the outcome of 
patient cohorts, the outcome of individual patients still remains quite unpredictable. 
Therefore additional information, for example on responsiveness towards a treatment 
approach, would provide a new perspective to refine outcome predictions. Standard 
treatments are recommended for AML patients because of known improved outcomes, 
however with the absence of a personalized testing system, patients that do not respond to 
standard treatments are left without targeted disease management. Hence, our findings 
provide a new perspective on the impact of drug treatments, both standard and those in trials, 
on cell-cell interactions in a 3D microenvironment. 
 
In summary, our introduced AML tri-culture model enables the extensive analysis of 
leukemia-vascular interactions. Relying on a thoroughly tuneable hydrogel matrix platform, 
AML cells have been for the first time successfully co-cultivated with both HUVECs and 
MSCs. Importantly, the approach offers exciting, unprecedented options for the visualization 
of AML-vascular interactions after the application of an anti-cancer compounds which is 
particularly important for investigating the impact of chemotherapeutics on post-application 
cellular responses.  The response of our model to the administration of anti-CXCR4 
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demonstrated mobilization of leukemia cells from the vascular niche, supporting the in vivo 
like behavior of the organotypic scaffold. Moreover, our 3D AML co-cultures showed a 
significantly increased resistance to chemotherapeutics compared with 2D cultures, 
confirming the higher clinical relevance of the introduced hydrogel-based model. We 
anticipate the approach to become instrumental in future extensive chemotherapeutic-
signaling inhibitor combination treatment analyses as well as in the definition of 
individualized treatment modalities for AML patients. Beyond that, identification of the 
signaling mechanisms of endothelial cells within the vascular niche that encourage AML 
growth or provide resistance to conventional chemotherapy might provide new insights into 
the development of new therapeutic strategies for AML patients.  
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Table 1. EC50 half-maximal response values for DNR in KG1a, MOLM13, MV4-11 and 
OCI-AML3 models. 
Model Daunorubicin  
EC50 (µM) 
KG1a 2D 0.105 
KG1a 3D 0.092 
KG1a Tri-culture 0.239 
MOLM13 2D 0.020 
MOLM13 3D 0.038 
MOLM13 Tri-culture 0.303 
MV4-11 2D 0.006 
MV4-11 3D 0.012 
MV4-11 Tri-culture 0.178 
OCI-AML3 2D 0.057 
OCI-AML3 3D 0.132 



























































Drug Observed binding constant (Kb) 
Daunorubicin (DNR) 0.87 ± 0.07 M-1 
Cytosine β-D-arabinofuranoside (AraC) 3 ± 0.3 M-1 
AMD3100 12.73 ± 0.17 M-1 
Sorafenib 0.79 ± 0.08 M-1 
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Figure Legends 
Figure 1. A three dimensional culture model of AML-vascular interactions. A) A 
biohybrid starPEG-heparin hydrogel was utilized which allows for the culture of AML mono-
cultures and tri-cultures with HUVECs and bone marrow-derived MSCs. B) Macroscopic 
image of final cast hydrogel before culture. Scale bar = 5 mm. Light microscope (C) and 
confocal images (D-H) of the OCI-AML3 cell line (as a representation of all cell lines 
utilized in this study) in tri-culture with HUVECs and MSCs after 7 days depicting CD31 (D, 
G, H) and CD45 (E, F) expression. Images display leukemia cell growth primarily along the 
vascular endothelial cells. Light microscope (I) and confocal images (J-K) of primary donor 
cells (pAML) from a patient with AML in tri-culture with HUVECs and MSCs after 7 days. 
Scale bar = 100 and 200µm as indicated. Images display the preference of leukemia cells to 
attach to and grow along vascular structures or within vascular branching.  
 
Figure 2. OCI-AML3 co-culture with either HUVEC or MSC. Confocal images of the 
OCI-AML3 cell line (as a representation of all cell lines utilized in this study) in co-culture 
with MSCs (left) or HUVECs (right) after 7 days of culture. Images display CD45+ leukemia 
cell growth along both network types. Scale bar = 100μm. 
 
Figure 3. 3D mono-cultures for the cultivation of AML spheroids. Growth of KG1a (A), 
MOLM13 (B), MV4-11 (C) and OCI-AML3 (D) cell lines was investigated in 3D. AML 
cells were cultivated in starPEG-heparin hydrogels (upper left image) or in MatrigelTM (lower 
left image). Comparison of cell growth (upper right graph) and spheroid size (lower right 
graph) over 14 days was performed using 3 different cross-linking degrees of hydrogel 
(γ0.75, γ1, γ1.5). E) Primary donor cells from 2 patients with AML were cultivated in 
starPEG-heparin hydrogels as a mono-culture. Cell line experiments were performed at least 
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2 times with 3 technical replicates (n=2). Data is displayed as mean ± SD. pAML 
experiments were performed one time in triplicate (n=1). Graph displays mean only. Cultures 
displayed heterogeneous distribution of cells, with each donor growing both as spheroids and 
single cells. 3 photographs per technical replicate were utilized for ImageJ spheroid 
measurements as a minimum. *Indicates statistical significance: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
Figure 4. Treatment of 3D mono-cultures and tri-cultures with DNR. A) Light 
microscope images of AML cell lines untreated and treated with 5µM DNR at day 7 post-
treatment. B) AML cells lines were treated with DNR for 24 h as 2D or 3D mono-cultures, or 
3D tri-cultures. Graphs display mean ± SEM. C) Mean spheroid diameter of 3D mono-
cultures after treatment with DNR (± SD). D) pAML from a patient with AML were 
cultivated as 3D mono-cultures (left confocal images) or 3D tri-cultures (right confocal 
images). Confocal cross-section (bottom confocal image) shows homogenous distribution of 
AML mono-culture throughout hydrogel. Mono-cultures (right graph) and tri-cultures (left 
graph) were treated with two concentrations of DNR. Graphs are displayed as mean only. 
Cell line experiments were performed at least 3 times in triplicate (n=3-4). pAML 
experiments were performed one time in triplicate (n=1). 3 photographs per technical 
replicate were utilized for ImageJ spheroid measurements as a minimum. Insert in (D) shows 
DNR uptake into pAML spheroid (lower right). *Indicates statistical significance between 
2D cultures and 3D tri-cultures: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Figure 5. Treatment of 3D AML tri-cultures with CXCR4 inhibitor, AMD3100. A) 
Confocal images of AML cell lines untreated (upper row) or treated (lower row) with 2.5 
µg/mL AMD3100. B) Percentage of AML cell-cell contact with HUVECs and MSCs when 
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compared with respective untreated control samples (left) and viability of AML tri-cultures 
after treatment with AMD3100 (right). C) pAML from a patient with AML untreated (left) or 
treated (right) with 2.5 µg/mL AMD3100. Data is displayed as mean ± SD.  D) Percentage of 
pAML contact with HUVECs and MSCs after AMD3100 treatment when compared with the 
untreated control sample (left) and viability of AML tri-cultures after treatment with 
AMD3100 (right). Data is displayed as mean only. Cell line experiments were performed at 
least 3 times in triplicate (n=3-4). pAML experiments were performed one time in triplicate 
(n=1). 3 photographs per technical replicate were utilized for ImageJ AML-vascular contact 
measurements as a minimum. *Indicates statistical significance between treated samples and 
respective control: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 Figure 6. ‚Induction’ treatment and ‚relapse’ of AML tri-cultures. A) Light microscope 
images of AML cell lines treated with human (hu) equivalent induction dose (left), murine 
(ms) equivalent induction dose (center) or treated with DNR only (right). Doses were based 
upon standard clinical treatments (hu) or standard murine model chemotherapy regimes (ms) 
of AML. B) Percentage of AML live cells after induction treatment and 14 days post-
treatment (relapse; R) when compared with the respective untreated control sample. C) 
Primary donor cells (pAML) from a patient with AML treated with hu induction (left). 
Percentage of pAML cell viability when compared with the untreated control sample (right). 
Experiments were performed one time in triplicate (n=1). 
